ERXC 103
Alternative Names: ERXC-103Latest Information Update: 04 Nov 2022
At a glance
- Originator EnduRx Pharmaceuticals
- Class Antineoplastics; Polymers
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Brain cancer; Glioblastoma
Most Recent Events
- 13 Oct 2022 Early research in Brain cancer in USA (unspecified route) (EnduRx Pharmaceuticals pipeline, October 2022)
- 13 Oct 2022 Early research in Glioblastoma in USA (unspecified route) (EnduRx Pharmaceuticals pipeline, October 2022)
- 13 Oct 2022 EnduRx Pharmaceuticals plans a phase 0 trial for Glioblastoma and Brain cancer (EnduRx Pharmaceuticals pipeline, October 2022)